Manchester emerges as genomics research hub

pharmafile | May 29, 2019 | News story | Research and Development Diagnostics, Manchester, UK, genomics, pharma 

­­Manchester, UK is emerging as a major hub for genomics research, according to a new firm set up in collaboration with the publicly funded Health Innovation Manchester.

Newly launched genomics research company Apis Assay Technologies has announced it will set up in Citylabs 1.0, a biomedical centre in Manchester which opened in 2014.

Positioned to benefit from the devolution of Greater Manchester’s NHS – which saw responsibility for Greater Manchester £6 billion NHS budget put in the hands of the city itself in February 2015 – Apis hopes to bring novel molecular diagnostics to the market.

Apis intends to move into the state of the art facility Citylabs 2.0 after the new development is completed in 2020.

The firm, which has been launched as part of alliance between Dutch firm Qiagen and Health Innovation Manchester, hopes to play a role in further developing Manchester as a major biotech hub.

Qiagen has longstanding links with Manchester – the firm’s Manchester operations having become a global hub for diagnostics development and research.

“Our shared vision is to create a globally leading genomics campus for innovation, translational science and molecular diagnostics, employing over 1,500 highly skilled people “, said Rowena Burns, Chair of Health Innovation Manchester.

“This is a major development for life sciences in Manchester – and across the North – and a testament to our long-standing history of forming public-private partnerships to support the creation of jobs, growth, address the health needs of local people, while also making an important international contribution to improved diagnosis and treatment of disease.”

Peer M. Schatz, Chief Executive Officer of QIAGEN commented: “This collaborative initiative can serve as an incubator for translating genomic biomarkers into clinical use. We are certain that the people of greater Manchester and patients all over the world will benefit from advanced diagnostic insights.”

Louis Goss

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …

Tempus receives FDA Premarket Approval for in vitro diagnostic scan

US-based artificial intelligence (AI) and precision medicine company Tempus has announced that the US Food …


Long COVID: 15 studies launched with £19.6 million government funding

The UK government has announced the launch of 15 new extensive studies, backed by £19.6 …

Latest content